This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Conformis, Inc. Announces Board Changes CI
Conformis, Inc.(NasdaqCM:CFMS) dropped from NASDAQ Composite Index CI
Restor3D, Inc. completed the acquisition of Conformis, Inc. from shareholders. CI
Conformis, Inc.(NasdaqCM:CFMS) dropped from S&P TMI Index CI
Conformis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Earnings Flash (CFMS) CONFORMIS Posts Q2 Revenue $13M MT
Sector Update: Health Care Stocks Lower Late Friday MT
Sector Update: Health Care MT
Top Midday Gainers MT
Global markets live: 3M Company, Meta, Moderna, Carmax, Shell... Our Logo
It just won't go away Our Logo
Sector Update: Health Care Stocks Decline Premarket Friday MT
Wall Street Set to Open Lower Ahead of June's Flash PMI; Oil Prices Drop Sharply MT
Sector Update: Health Care MT
US Futures Trend Lower Premarket Friday Ahead of June's Flash PMI MT
Top Premarket Gainers MT
ConforMIS Agrees to be Acquired by restor3d MT
Restor3D, Inc. entered into a definitive merger agreement to acquire Conformis, Inc. from shareholders for $17.9 million. CI
Conformis, Inc. Announces Resignation of Robert S. Howe as Treasurer, Effective June 9, 2023 CI
Conformis, Inc. Announces Chief Financial Officer Changes, Effective June 9, 2023 CI
Conformis, Inc. Announces Board Changes CI
Oppenheimer Downgrades ConforMIS to Perform From Outperform, Removes $6 Price Target MT
Transcript : Conformis, Inc., Q1 2023 Earnings Call, May 08, 2023
Conformis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Earnings Flash (CFMS) CONFORMIS Reports Q1 Revenue $12.8M, vs. Street Est of $12.6M MT
Chart Conformis, Inc.
More charts
Conformis, Inc. is a medical technology company. The Company is engaged in the development, manufacturing, and sales of patient-specific products and instrumentation that are individually sized and shaped to fit each patient's various knee and hip anatomy. The Company offers knee replacement products and knee replacement products. The Company's product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant Platinum Services Program, as well as data-informed, standardized solutions that combine many benefits of personalization with an off-the-shelf system. Its sterile, just-in-time, Surgery-in-a-Box delivery system is available with all of its implants and personalized, single-use instruments. The Company owns or in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.
More about the company
  1. Stock Market
  2. Equities
  3. CFMS Stock
  4. News Conformis, Inc.
  5. Conformis : Warns on Q3 Sales as COVID-19 Delays Surgeries; Shares Sag